Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP976 | DOI: 10.1530/endoabs.81.EP976

Taher Sfar University Hospital, ENT, Mahdia, Tunisia


Introduction: Anaplastic thyroid cancers are undifferentiated malignancies accounting for 2% of thyroid cancers.

Objective: To study the clinical, evolutionary and therapeutic characteristics of these carcinomas.

Materials and methods: A retrospective study covering 7 cases collected at our ENT department between 1994 and 2021.

Results: They were 6 women and one man with an average age of 50 (41-78). The reason for consultation was cervical swelling 100% of the time. Dyspnea was noted in 2 cases. The average duration of the symptomatology was 14 weeks. The tumor was plunging into the mediastinum in 2cas. In 4 cases, there was an invasion of the trachea and/or sub-hyoid muscles. Lymph node metastases were noted in all patients, bone in 2 patients and lung in 1 case. Histological confirmation of the diagnosis was made on thyroidectomy in 3 cases, and on a micro-biopsy of the thyroid gland in 4 cases. A tracheotomy was done in 3 cas. Three patients had a total thyroidectomy. The rest of the patients were inoperable. Radiation chemotherapy was indicated in all patients. Six patients died after an average delay of 11 months [8 months to 13 months]. A patient is still alive with a one-month decline.

Conclusion: Anaplastic thyroid carcinoma is a cancer with a dark prognosis. Patients in the localized disease stage can expect better survival. Therapeutic research explores targeted therapies that block the EGF receptor or inhibit neoplastic angiogenesis.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts